Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AdAlta Limited

http://www.adalta.com.au/

Latest From AdAlta Limited

UK Studies More Antibody And Viral Test Options In COVID-19 Control Program

While COVID-19 testing capacity rises slowly the in UK, the scientific community is pressing to develop the range of test types to get the numbers up further to secure sustainable control of the disease.  

United Kingdom Policy

Developing Antibody Tests Is Technically The Biggest COVID-19 Challenge Yet

The COVID-19 antibody tests that so far have gone through the validation process have not proven accurate enough to be rolled out for public use, says the UK. A new rapid test consortium is working on a solution.

United Kingdom Coronavirus COVID-19

Deal Watch: Sandoz Licenses Posimir For Pain As Durect Generates Data For Resubmission

Sandoz acquires rights to extended-release bupivacaine once held by Nycomed and Hospira in deal paying Durect $20m up front. Video interview: Partners Elasmogen and Feldan collaborate with Amgen.

Deals M & A

Ossianix Cracks Open The Blood-Brain Barrier

By using the binding region of shark antibodies as a carrier to cross the blood-brain barrier, Ossianix reckons it has made significant progress against an issue that has held back the development of CNS-active neurological therapies.

Platform Technologies Research & Development
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register